Eikon Therapeutics Inc (EIKN)
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company focused on developing medicines for serious unmet medical needs. The company uses a platform designed to precisely characterize protein interactions in living cells, supporting its drug development programs. Its pipeline includes EIK1001, a systemically administered TLR 7/8 dual-agonist intended to stimulate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, selective PARP1 inhibitors being studied in ovarian, breast, prostate, and pancreatic cancers; EIK1004, which is also being developed in a brain-penetrant form for brain metastases and primary brain malignancies; EIK1005, a WRN helicase inhibitor for MSI-high tumors; and EIK1006, a next-generation androgen receptor antagonist with activity against multiple clinically emergent androgen receptor variants. Incorporated in 2019, Eikon Therapeutics is based in Millbrae, California, and its common stock is listed on NASDAQ under the ticker EIKN.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-EIKN
|
$11.75
|
21.9% Upside
|
Undervalued
|
$24.80
|
157.3% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
September 2, 2026
|
-1.5x
|
0.9x
|
—
|
522.4 M
|
181.3 M
|
32.8%
|
55.1%
|
-1.2
|
—
|
72.6%
|
